Metagenomi (MGX) Competitors $2.25 -0.05 (-2.17%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.22 -0.02 (-1.11%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MGX vs. MRNA, PRTA, CADL, GLUE, RNAC, FHTX, RCKT, INBX, ABEO, and AVIRShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Moderna (MRNA), Prothena (PRTA), Candel Therapeutics (CADL), Monte Rosa Therapeutics (GLUE), Cartesian Therapeutics (RNAC), Foghorn Therapeutics (FHTX), Rocket Pharmaceuticals (RCKT), Inhibrx Biosciences (INBX), Abeona Therapeutics (ABEO), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Its Competitors Moderna Prothena Candel Therapeutics Monte Rosa Therapeutics Cartesian Therapeutics Foghorn Therapeutics Rocket Pharmaceuticals Inhibrx Biosciences Abeona Therapeutics Atea Pharmaceuticals Metagenomi (NASDAQ:MGX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation. Which has better earnings and valuation, MGX or MRNA? Metagenomi has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetagenomi$52.29M1.61-$78.06M-$2.11-1.07Moderna$3.24B3.30-$3.56B-$8.73-3.16 Do analysts rate MGX or MRNA? Metagenomi presently has a consensus price target of $13.00, suggesting a potential upside of 477.78%. Moderna has a consensus price target of $46.11, suggesting a potential upside of 67.07%. Given Metagenomi's stronger consensus rating and higher possible upside, equities research analysts plainly believe Metagenomi is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Moderna 4 Sell rating(s) 17 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Is MGX or MRNA more profitable? Moderna has a net margin of -105.67% compared to Metagenomi's net margin of -172.21%. Moderna's return on equity of -28.69% beat Metagenomi's return on equity.Company Net Margins Return on Equity Return on Assets Metagenomi-172.21% -31.21% -22.21% Moderna -105.67%-28.69%-21.94% Which has more risk & volatility, MGX or MRNA? Metagenomi has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Do institutionals & insiders have more ownership in MGX or MRNA? 75.3% of Moderna shares are held by institutional investors. 17.8% of Metagenomi shares are held by company insiders. Comparatively, 11.0% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to MGX or MRNA? In the previous week, Moderna had 42 more articles in the media than Metagenomi. MarketBeat recorded 43 mentions for Moderna and 1 mentions for Metagenomi. Moderna's average media sentiment score of 0.26 beat Metagenomi's score of 0.00 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 10 Very Positive mention(s) 1 Positive mention(s) 14 Neutral mention(s) 15 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryModerna beats Metagenomi on 10 of the 17 factors compared between the two stocks. Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.98M$2.46B$5.49B$9.52BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-1.078.9728.7823.81Price / Sales1.61437.65372.2066.04Price / CashN/A157.7635.4557.96Price / Book0.364.838.275.54Net Income-$78.06M$31.62M$3.25B$259.28M7 Day Performance-7.41%-5.28%-3.70%-4.64%1 Month Performance39.75%4.38%4.34%4.41%1 Year Performance-38.02%-2.49%25.90%17.95% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi2.4384 of 5 stars$2.25-2.2%$13.00+477.8%-35.7%$85.98M$52.29M-1.07236MRNAModerna4.4709 of 5 stars$33.91-0.7%$46.11+36.0%-70.7%$13.21B$3.14B-3.885,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap DownPRTAProthena3.2473 of 5 stars$6.87+2.8%$31.50+358.5%-69.5%$359.56M$135.16M-3.30130News CoverageUpcoming EarningsCADLCandel Therapeutics2.1899 of 5 stars$6.86-2.3%$22.00+220.7%+13.5%$351.72M$120K-5.1260Gap DownGLUEMonte Rosa Therapeutics1.2679 of 5 stars$5.55-2.1%$15.33+176.3%+9.6%$348.76M$75.62M69.3890RNACCartesian Therapeutics1.4107 of 5 stars$13.70+2.8%$40.00+192.0%-20.3%$345.97M$38.91M-0.2664Upcoming EarningsFHTXFoghorn Therapeutics2.4956 of 5 stars$6.50+5.0%$12.13+86.5%-23.3%$345.04M$22.60M-4.78120Upcoming EarningsGap DownRCKTRocket Pharmaceuticals4.8355 of 5 stars$3.11-1.0%$17.87+474.5%-86.5%$335.31MN/A-1.18240Trending NewsUpcoming EarningsINBXInhibrx Biosciences1.3548 of 5 stars$24.57+6.5%N/A+48.2%$334.11M$200K0.21166ABEOAbeona Therapeutics3.8538 of 5 stars$6.62+1.4%$19.25+190.8%+34.9%$334.05M$3.50M-5.2190News CoverageAVIRAtea Pharmaceuticals1.692 of 5 stars$3.79-2.8%$6.00+58.3%-4.4%$333.76MN/A-2.3070News CoverageUpcoming Earnings Related Companies and Tools Related Companies Moderna Competitors Prothena Competitors Candel Therapeutics Competitors Monte Rosa Therapeutics Competitors Cartesian Therapeutics Competitors Foghorn Therapeutics Competitors Rocket Pharmaceuticals Competitors Inhibrx Biosciences Competitors Abeona Therapeutics Competitors Atea Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGX Stock Alerts